Navigation Links
Novel experimental agent is highly active in CLL patients, interim study shows
Date:12/11/2011

COLUMBUS, Ohio An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy. The agent, called PCI-32765, is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) is available to discuss the findings that were presented today (12/13) at the 53rd Annual Meeting of the American Society of Hematology in San Diego.

Study co-leader Dr. Susan O'Brien of The University of Texas M.D. Anderson Cancer Center reported the analysis, which involves 61 patients who have relapsed and whose cancer no longer responds to standard CLL therapy. Of these patients, 27 received a drug dose of 420 milligrams (mg) and 34 received a drug dose of 840 mg.

This study found that 70 percent of patients in the 420-mg group had either a complete or partial remission to treatment after 10 months of follow-up.

"These interim findings are truly exciting because they provide additional evidence that PCI-32765 is a highly active oral therapeutic that produces a high rate of durable remissions the remissions last months on end with acceptable toxicity in relapsed and refractory CLL," Byrd says. "These responses last for many months in part because patients are willing to remain on the drug since the side effects are very tolerable," he notes.

Complete remission means there is no detectable CLL anywhere in the body; partial remission means that the individual's disease volume has decreased 50 percent or more in a sustained manner.

Patients enrolled in this cohort of the ongoing phase II clinical trial are individuals with relapsed CLL, all of whom had two or more earlier treatments followed by recurrent disease.

"Usually patients with highly resistant and refractory CLL would have progressed and possibly died by this time, but 82 percent remain on PCI-32765 and continue to improve." Byrd says.
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... enrichment program serving families of greater Dubuque, IA. The current campaign fundraises for ... honorably discharged veterans. Donations to Veteran’s Freedom Center may now be made here: ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... focused resources for veterinary professionals across the United States. The whole food nutrient ... of their patients and giving dog, cat and horse owners’ peace of mind. ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... presented a talk highlighting the organization’s successful Care Transitions program at ... The talk was titled “Minimizing Costs in the Post-Acute Environment Through Effective Transitions ...
(Date:5/5/2016)... CA (PRWEB) , ... May 05, 2016 , ... In ... nursing firm, is encouraging people all over the United States to thank a nurse ... 12, Aya Healthcare will donate $5 to the American Red Cross of San Diego/Imperial ...
(Date:5/5/2016)... ... May 05, 2016 , ... United Collection Bureau, Inc. (UCB) announces Sarah ... than 15 years of experience within the healthcare revenue cycle industry. With a primary ... Director of Patient Financial Services at Spectrum Health. While at Spectrum Health, Clark helped ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... New York , May 4, 2016 ... by Transparency Market Research entitled "Brain Computer Interface Market - ... 2016 - 2024," the  global brain computer interface (BCI) market ... by 2024. The market is estimated to expand at ... from 2016 to 2024. A BCI device ...
(Date:5/4/2016)... May 4, 2016 In ... a series of free workshops across ... requirements for Good Distribution Practices (GDP). Good ... ensures that products are consistently stored, transported and handled ... (MA) or product specification. Only a few years ago, ...
(Date:5/4/2016)... 2016 Research and ... Actinic Keratosis Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Landscape Highlights 2016, provides comprehensive insights into ... Actinic Keratosis market valuations and forecast, Actinic ...
Breaking Medicine Technology: